

Contact: Hariharan Subramanian
PancreaSolve, Inc.
Phone: (617) 553-1015
701 Concord Avenue
Cambridge, MA 02138
info@pancreasolve.com
www.pancreasolve.com

PancreaSolve™

PRESS RELEASE

PancreaSolve, Inc. is incorporated as a Delaware corporation

Cambridge, October 31, 2015: PancreaSolve, Inc. is incorporated as a Delaware corporation. PancreaSolve is a joint venture between CytoSolve, Inc. and MD Anderson Cancer Center.

Based on proprietary in silico technology and a feedback systems design that mines existing peer-reviewed literature for validated molecular mechanisms, while reusing scientific data from wet lab and clinical trials, PancreaSolve offers a revolutionary and proven integrative information-centric platform that accurately model complex molecular mechanisms in pancreatic cancer. These models enable rapid in silico testing for the development of single and multi-combination compounds for drugs by optimizing in vitro and in vivo testing. PancreaSolve will be headed by Dr. Shiva Ayyadurai as the Chief Executive Officer.

PancreaSolve is headquartered in Cambridge, MA. PancreaSolve uses CytoSolve's revolutionary technology for in silico mechanistic modeling is accelerating discovery and development of single and multi-combination therapeutics for pancreatic cancer.

The University of Texas MD Anderson Cancer Center is one of the world's most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is a premier cancer center in the world, based on the excellence in research-driven patient care and cutting-edge science.